Publications
Efficace F, Koinig K, Cottone F, Bowen D, Mittelman M, Sommer K, Langemeijer S, Culligan D, Filanovsky K, Storck M, Smith A, van Marrewijk C, Dugas M, Stojkov I, Siebert U, de Witte T, Stauder R. Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project. Cancer Medicine 2023 (in press).
Oliva E, Platzbecker U, Fenaux P, Garcia-Manero G, LeBlanc T, Patel B, Kubasch A, Sekeres M. Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 2021; Volume 50, Article 100851.
Abel G, Klepin H, Magnavita E, Jaung T, Lu W, Shallis R, Hantel A, Bahl N, Dellinger-Johnson R, Winer E and Zeidan A. Peri-transfusion quality of life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 Oct; 61(10):2830-2836.
Efficace F, Koinig K, Cottone F, Bowen D, Mittelman M, Langemeijer S, Culligan D, Filanovsky K, Abel G, Storck M, Smith A, Van Marrewijk C, Dugas M, de Witte T, Stauder R. Validation of the QUALMS Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project [abstract]. Blood. 2021.
Abel G, Klepin H, Magnavita E, Jaung T, Lu W, Shallis R, Hantel A, Bahl N, Dellinger-Johnson R, Winer E and Zeidan A. Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes [abstract]. Blood. 2020.
Trudeau JJ, He J, Rose E, Panter C, Randhawa S, Gater A. Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes. J Patient Rep Outcomes. 2020 Aug 26;4(1):69.
Abel G, Efficace F, Buckstein R, Tinsley S, Jurcic J, Martins Y, Steensma D, Watts C, Raza A, Lee S J, List A, and Klaassen R. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica 2016; 101(6): 781-8.
Abel G, Klaassen, R, Lee, S, Young, N., Canella, L., Steensma, D., and Efficace, F. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood 2014; 123(3): 451-2.
Oliva E, Platzbecker U, Fenaux P, Garcia-Manero G, LeBlanc T, Patel B, Kubasch A, Sekeres M. Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 2021; Volume 50, Article 100851.
Abel G, Klepin H, Magnavita E, Jaung T, Lu W, Shallis R, Hantel A, Bahl N, Dellinger-Johnson R, Winer E and Zeidan A. Peri-transfusion quality of life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 Oct; 61(10):2830-2836.
Efficace F, Koinig K, Cottone F, Bowen D, Mittelman M, Langemeijer S, Culligan D, Filanovsky K, Abel G, Storck M, Smith A, Van Marrewijk C, Dugas M, de Witte T, Stauder R. Validation of the QUALMS Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project [abstract]. Blood. 2021.
Abel G, Klepin H, Magnavita E, Jaung T, Lu W, Shallis R, Hantel A, Bahl N, Dellinger-Johnson R, Winer E and Zeidan A. Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes [abstract]. Blood. 2020.
Trudeau JJ, He J, Rose E, Panter C, Randhawa S, Gater A. Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes. J Patient Rep Outcomes. 2020 Aug 26;4(1):69.
Abel G, Efficace F, Buckstein R, Tinsley S, Jurcic J, Martins Y, Steensma D, Watts C, Raza A, Lee S J, List A, and Klaassen R. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica 2016; 101(6): 781-8.
Abel G, Klaassen, R, Lee, S, Young, N., Canella, L., Steensma, D., and Efficace, F. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood 2014; 123(3): 451-2.